Radiotherapy With Pembrolizumab in Metastatic HNSCC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second
line therapy of metastatic head and neck squamous cell carcinoma.